Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.3.1 (alkaline phosphatase)
47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

[23 (S), 25 (R)]-1 alpha,25-Dihydroxyvitamin D3-26,23-lactone [( 23 (S),25 (R)]-1 alpha,25-(OH) 2D3-26,23-lactone) increased dose-dependently alkaline phosphatase activity in osteoblastic cells, clone MC3T3-E1, in medium containing 0.1% bovine serum albumin. The maximal stimulated enzyme activity per mg protein was 1.6-fold over that of control cultures at 250 pg/ml. The metabolite also increased collagen synthesis in a dose-related fashion. On the other hand, [23 (S),25 (R)]-1 alpha,25-(OH)2D3-26,23-lactone decreased slightly but significantly 45Ca mobilization, and blocked the resorptive action of 1 alpha,25-dihydroxyvitamin D3 but not that of parathyroid hormone, in mouse calvaria in organ culture. These results indicate that [23 (S),25 (R)]-1 alpha, 25-(OH)2D3-26,23-lactone stimulates the differentiation of osteoblasts and inhibits bone resorption in vitro.
...
PMID:The unique action for bone metabolism of 1 alpha,25-(OH)2D3-26,23-lactone. 383 77

The biochemical parameters of calcium metabolism were measured in patients suffering from bone metastases of prostatic origin. In 14 patients with sclerotic bone lesions, serum calcium and serum phosphorus were significantly lower than in controls. Serum alkaline phosphatase levels, which reflect osteoclastic bone formation, and urinary hydroxyproline, which reflects osteoclastic bone resorption, were both increased. 25-Hydroxyvitamin D (25-OHD) levels were appropriate for the age of the patients but serum immunoreactive parathyroid hormone (iPTH) and 1,25-Dihydroxyvitamin D (1,25-(OH)2D) levels were significantly increased. In contrast, no significant changes wee noted in 3 patients with pure osteolytic lesions. We conclude that the patients with sclerotic bone metastases have a high bone formation which frequently induces a secondary hyperparathyroidism and increased 1,25-(OH) 2D levels. A calcium and/or vitamin D supplement could therefore be advantageous in patients having symptomatic hypocalcemia or osteomalacia.
...
PMID:Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin. 383 94

The relationship between growth and plasma alkaline phosphatase activity differs in the preterm infant when compared with older children and adolescents. 18 preterm infants were studied over the first 12 postnatal weeks; growth velocity and plasma alkaline phosphatase activity were measured serially. Plasma calcium, inorganic phosphate, the vitamin D metabolites and parathyroid hormone were assayed at a median age of 3 and 6 weeks. There was an overall significant negative correlation between growth and plasma alkaline phosphatase activity (r = -0.37; P less than 0.005); this was more marked in a group where the plasma alkaline phosphatase activity exceeded the preterm reference range. Plasma 1,25-dihydroxycholecalciferol and inorganic phosphate were lower in this group at 3 weeks but not at 6 weeks when compared with infants where plasma alkaline phosphatase activity did not exceed the reference range. There was no difference in caloric intake between the groups. In the preterm infant biochemical rickets is common and unlike older children and adolescents an increase in plasma alkaline phosphatase activity correlates with decreased rather than increased growth.
...
PMID:Growth velocity and plasma alkaline phosphatase activity in the preterm infant. 383 82

The possible relationship between red blood cell (RBC) osmotic fragility and secondary hyperparathyroidism (HPT) in chronic renal failure was examined in 23 uremic patients on conservative therapy and in 42 patients on maintenance hemodialysis. Secondary HPT was evaluated by means of serum biochemistry (parathyroid hormone, calcium, phosphorus, and alkaline phosphatase) and radiographic examinations (X-ray films of the hand skeleton). This study showed increased RBC osmotic fragility in uremic patients when compared with controls, with no difference between those on conservative therapy and those on maintenance hemodialysis. No correlation between RBC osmotic fragility and the hematochemical changes associated with secondary HPT was found. No difference in RBC osmotic fragility was observed with regard to the activity (alkaline phosphatase) and the severity (X-ray findings) of secondary HPT. Effective treatment of secondary HPT by either pharmacological means (1,25-dihydroxycholecalciferol) or surgical removal was not associated with consequent improvement in RBC osmotic fragility. It is concluded that secondary HPT is probably not a major factor influencing RBC osmotic fragility in chronic renal failure.
...
PMID:Lack of relation between secondary hyperparathyroidism and red blood cell osmotic fragility in chronic renal failure. 384 May 75

To test the importance of vitamin D metabolites on intramuscular implants of demineralized bone, four-month-old rats were given either 1a,25-(OH)2D3 or 24R,25-(OH)2D3, or a combination of both metabolites, and sacrificed at intervals ranging from five to 35 days after implantation. Histologically there was a reduced ingrowth of mesenchymal cells into the implanted matrix cylinders in the presence of 1a,25-(OH)2D3; the reduction was followed by decreased total DNA and protein values until the 16th experimental day. At 35 days postimplantation, the quantity of new bone was the same in all treated groups. However, 1a,25-(OH)2D3 increased the alkaline phosphatase activity 60%-110% (depending on the denominator used). The metabolite 24R,25-(OH)2R3 had no effect on cell growth or the alkaline phosphatase activity. These results provide evidence for the inhibitory effect of 1a,25-(OH)2D3 on mesenchymal cell growth and its stimulatory effect on osteoblasts, which are responsible for increased alkaline phosphatase activity and new bone formation in vivo.
...
PMID:1a,25-Dihydroxyvitamin D3 stimulates alkaline phosphatase activity and inhibits soft-tissue proliferation in implants of bone matrix. 387 7

The possible relationship between erythrocyte (RBC) function and secondary hyperparathyroidism (HPT) was examined in 35 uremic patients on maintenance hemodialysis. Mechanical tests (i.e., osmotic fragility and deformability) were used to assess RBC function. Secondary HPT was evaluated by means of serum biochemistry (parathyroid hormone, calcium, phosphorus, and alkaline phosphatase) and radiographic examinations (X-ray films of the hand skeleton). Sixteen sex and age-matched normal volunteers acted as controls. This study shows that the mechanical properties of RBC were indeed markedly altered in hemodialysis patients when compared with controls. No significant correlations between either the osmotic fragility or the deformability of RBC and the hematochemical changes associated with secondary HPT were found. No differences in RBC function tests were found as far as the activity (alkaline phosphatase) or the severity (X-ray findings) of secondary HPT are concerned. Effective treatment of secondary HPT by either pharmacological means (1,25-dihydroxycholecalciferol) or surgical removal was not associated with consequent improvement in RBC function. These findings clearly speak against secondary HPT as a major cause of RBC dysfunction in uremic patients on maintenance hemodialysis.
...
PMID:Osmotic fragility of erythrocytes, cell deformability and secondary hyperparathyroidism in uremic patients on maintenance hemodialysis. 398 1

Additional administration of vitamin D3 at a physiological dose of 0.25 microgram daily into rats with femur fracture within 4 weeks did not affect the specific weight and chemical composition (content of Ca2+, P) in diaphyses of intact and impaired femurs as well as the content of Ca2+. Pi and activity of alkaline phosphatase in blood serum of the animals. At a higher dose 2.5 microgram daily vitamin D3 increased concentration of Pi in blood serum but did not alter the other parameters studied. Physiological doses of 1,25-dihydroxycholecalciferol (1.25 (OH)2D3) and 24,25-dihydroxycholecalciferol (24,25 (OH)2D3) (00.3 microgram and 0.25 microgram daily, respectively) did not affect the specific weight and composition of the impaired diaphyses, content of Ca2+ and activity of alkaline phosphatase in blood but increased slightly the Pi concentration. After a 5-fold increase in the dose of 1,25(OH)2D3 (0.15 microgram daily) specific weight and content of Ca2+ were decreased in the impaired bones with simultaneous increase in concentration of Ca2+, Pi and activity of alkaline phosphatase in blood serum. These data suggest that reparation was impaired under the conditions of acceleration of the bone tissue resorption. Increased doses of 24, 25(OH)2D3 (1.25 micrograms daily) stimulated the increase in specific weight and mineralization of the impaired bones and normalized the increased alkaline phosphatase activity in blood serum. Clinical examination of 24,25(OH)2D3 could be recommended as a drug stimulating the reparation under conditions of bone fracture.
...
PMID:[Effect of vitamin D3 and its metabolites 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol on callus mineralization in rats with femoral fracture]. 629 67

Clone MC3T3-E1 cells isolated from newborn mouse calvaria had the same type of alkaline phosphatase (ALP) as that found in adult mouse calvaria (the liver-bone-kidney type), as judged by polyacrylamide gel electrophoresis as well as by heat lability and amino acid inactivation. The effects of prostaglandin E2 (PGE2), parathyroid hormone (PTH), 1,25 dihydroxycholecalciferol [1,25(OH)2D3], and adenosine-3',5'-cyclic monophosphate (cAMP) analogs on ALP were investigated. PGE2 and 1,25(OH)2D3 increased ALP activity in dose-related manner with a maximal effect at concentrations of 10 ng/ml and 40 pg/ml, respectively. N6,O2-dibutyryl adenosine-3',5'-cyclic monophosphate (DBcAMP) also induced an increase in ALP activity in a dose-related fashion with a maximal effect at a concentration of 0.5 mM which was 2.2-fold over that of the controls. Induced ALP was of the "liver-bone-kidney" type. Antinomycin D and cycloheximide inhibited the increase in ALP activity induced by DBcAMP. The level of ALP was elevated by 8-bromo-adenosine-3',5'-cyclic monophosphate and theophylline, but not by N6,O2-dibutyryl guanosine-3',5'-cyclic monophosphate and sodium butyrate. Moreover, PGE2 dramatically increased the level of cAMP in the cells with a maximal effect at a concentration of 10 ng/ml, indicating that PGE2 and DBcAMP induce an increase of ALP activity in clone MC3T3-E1 cells by increasing the cAMP level; PTH did not affect enzyme activity and cAMP level in the cells.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:The effects of prostaglandin E2, parathyroid hormone, 1,25 dihydroxycholecalciferol, and cyclic nucleotide analogs on alkaline phosphatase activity in osteoblastic cells. 632 41

Seventy-six patients receiving regular haemodialysis, without biochemical or radiological evidence of renal osteodystrophy, entered a five-year double-blind placebo-controlled trial of calcitriol (1,25-dihydroxycholecalciferol) in the prevention of bone disease. Significantly more patients on placebo developed bone disease as judged by a sustained elevation of plasma alkaline phosphatase or the development of sub-periosteal erosions on hand radiographs. Serum parathyroid hormone fell significantly in the patients receiving calcitriol and was significantly lower than in patients receiving placebo. It is concluded that calcitriol delays and may prevent the development of metabolic bone disease in patients receiving regular haemodialysis therapy.
...
PMID:Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients. 634 40

1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] stimulates the alkaline phosphatase of rat and human osteoblast-like cells in culture. Here the mechanism of this effect was investigated using the rat osteogenic sarcoma cell line ROS 17/2-8. We found that 50% maximum alkaline phosphatase stimulation is elicited by 1,25(OH)2D3 at 7 X 10(-10) M. The concentration of serum in the culture medium influences inversely the effective 1,25(OH)2D3 concentration. Increased alkaline phosphatase appears after a lag period of cell exposure to 1,25(OH)2D3 which is between 8 and 24 h; during 96 h culture in the presence of 1,25(OH)2D3 the enzyme activity continues to rise. Cycloheximide (0.1-1 micrograms/ml) added in the cultures for 3 days or actinomycin-D (1-30 ng/ml) added for 24 h inhibit the 1,25(OH)2D3 effect on alkaline phosphatase in a dose-dependent fashion; withdrawal of cycloheximide restores the responsiveness of cells to 1,25(OH)2D3 completely, but withdrawal of actinomycin-D restores cell responsiveness only partially. These findings suggest that 1,25(OH)2D3-induced stimulation of alkaline phosphatase in the osteoblast-like cells involves genome activation and de novo protein synthesis.
...
PMID:Mechanism of action of 1,25-dihydroxyvitamin D3-induced stimulation of alkaline phosphatase in cultured osteoblast-like cells. 635 97


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---